Pharmaceutical

EC approves argenx’s efgartigimod alfa for CIDP treatment

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Jun 23, 2025 - 06:00
EC approves argenx’s efgartigimod alfa for CIDP treatment
The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.
Read the original article

Tags:

Previous Article

Early Lipids Boost Cerebellar Metabolism in Preemies

Next Article

From discovery to delivery: making therapies reach patients faster

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research

STAT+: J&J to emphasize cancer drugs and stop much of i...

Dec 5, 2023

HHS fills key vaccine advisory panel slots

HHS fills key vaccine advisory panel slots

Feb 15, 2024

HHS gives thumbs down to bluebird’s fertility support programme

HHS gives thumbs down to bluebird’s fertility support p...

Jul 24, 2024